Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. VINGE ADVISES INDUSTRIFONDEN IN CONJUNCTION WITH INVESTMENT IN POLIGHT
Mandate

VINGE ADVISES INDUSTRIFONDEN IN CONJUNCTION WITH INVESTMENT IN POLIGHT

February 05, 2015

Vinge has advised Indistrifonden in connection with its SEK 50 million investment in poLight.  poLight is a Norwegian company which has developed a new type of autofocus actuated lense for use in, among other things, mobile phones. In total, the private placement amounts to SEK 150 million and the funds will be used for a planned IPO.

Industrifonden is one of Sweden’s largest investors in small and medium sized enterprises. The fund has assets under management of SEK 3.8 billion and has invested in approximately 90 companies with the areas of technology, cleantech, life science and industry.

Vinge’s team consisted of responsible partner Johan Larson together with associate Mårten Svensson.

Related

Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of MedMera Bank AB

 Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of all shares in MedMera Bank AB from Kooperativa Förbundet for a total consideration of SEK 1,960 million. The transaction positions Morrow Bank as a leading Nordic platform in consumer finance with combined gross loans of SEK 28.2 billion.
March 24, 2026

Vinge advises NEWS, a portfolio company of Litorina, in connection with the sale of Skandinavisk Kommunalteknik, FANN VA-Teknik and Alunda Polyeten to Wienerberger AG

 Vinge advises Northern Environmental and Water Solutions AB (“NEWS”), a portfolio company of Litorina, in connection with the sale of the operating subsidiaries Skandinavisk Kommunalteknik, FANN VA-Teknik and Alunda Polyeten to Wienerberger AG (Vienna Stock Exchange: WIE). The transaction is expected to be completed in Q2 2026.
March 24, 2026

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026